SCHEMBL138132

SCHEMBL138132

COC(=O)c1cc(Br)nc(-c2ccccc2OCc2ccccc2)c1N

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 3/20 0.44
MCL1 Q07820 1/20 0.43
VDR P11473 1/20 0.43
HTT P42858 1/20 0.43
CNR1 P21554 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
DHODH Q02127 2/20 0.41
LRRK2 Q5S007 1/20 0.41
SMPD1 P17405 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL110167 0.85 MCL1 (0.46) MCL1CNR1DHODHSMPD1
SCHEMBL26604345 0.78 LRRK2 (0.48) LMNAHPGDLRRK2SMPD1HDAC1
SCHEMBL111300 0.76 ALDH1A1 (0.41) HPGDDHODHTDP1L3MBTL1
SCHEMBL978857 0.75 HTT (0.64) PTGER1HTTLMNAL3MBTL1
SCHEMBL26604406 0.75 HTT (0.53) PTGER1HTTLMNAHPGDTDP1
SCHEMBL110248 0.75 KDM4E (0.42) CNR1HPGDL3MBTL1
SCHEMBL23958640 0.74 LMNA (0.49) LMNAHPGDDHODHL3MBTL1
SCHEMBL26992628 0.74 LMNA (0.49) FFAR4LMNAHPGDLRRK2SMPD1
SCHEMBL16491109 0.74 FFAR4 (0.54) MCL1HTTFFAR4LMNAHPGD
SCHEMBL14891403 0.74 FFAR4 (0.54) FFAR4LMNAHPGDLRRK2SMPD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 PTGER1 1049/4885MCL1 36/4885VDR 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.